By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street

Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system.

Key Statistics

Ownership: Public

Web Site: Dynavax
Symbol: DVAX

Company News
Dynavax (DVAX) To Present Data On SD-101 In Combination With KEYTRUDA At The 2017 ASCO Annual Meeting 5/19/2017 9:07:10 AM
Dynavax (DVAX) Reports First Quarter 2017 Financial Results 5/8/2017 9:39:27 AM
Dynavax (DVAX) Announces FDA Advisory Committee Meeting To Review HEPLISAV-B 4/3/2017 11:02:59 AM
Dynavax (DVAX) Announces Upcoming Data Presentations For Three TLR9 Agonist Programs At The 2017 AACR Annual Meeting 3/20/2017 8:34:12 AM
Dynavax (DVAX) Reports Fourth Quarter And Year End 2016 Financial Results And Company Update 3/13/2017 7:21:21 AM
Bay Area’s Dynavax (DVAX) Shifts Focus to Immune-Oncology, Cuts 40% of Staff 3/13/2017 5:59:39 AM
Dynavax (DVAX) Presents Promising Clinical Data From Lead Immuno-Oncology Candidate, SD-101, At The International Congress On Targeted Anticancer Therapies 3/6/2017 10:02:34 AM
Dynavax (DVAX) To Present At Cowen and Company 37th Annual Health Care Conference 3/2/2017 7:46:26 AM
Dynavax (DVAX) Announces FDA Acceptance For Review Of Its Complete Response To November 2016 CRL And PDUFA Action Date For HEPLISAV-B 3/1/2017 9:45:37 AM
Dynavax (DVAX) To Present At The 2017 RBC Capital Markets Global Healthcare Conference 2/16/2017 8:11:03 AM